Additional treatment for AML patients now available in England
Leukaemia Care is pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patients with a FLT3 mutation now have access to quizartinib, in combination with chemotherapy, thanks to a decision made by the National Institute for Health and Care Excellence (NICE) today.